Business Wire

Nord Anglia Education and Boston College to Demonstrate the Power of Metacognition at the European Conference on Education

12.7.2024 16:16:00 EEST | Business Wire | Press release

Share

Dr Kate Erricker, Group Head of Education Research and Global Partnerships at Nord Anglia Education, and Dr Damian Bebell, Assistant Professor at the Lynch School of Education and Human Development, Boston College, will lead a workshop on metacognition at the European Conference on Education (ECE) on Saturday 13 July 2024.

Titled “Exploring the Implementation and Outcomes of a Global Metacognition Project”, the workshop will explore how metacognition can improve learning in classrooms and showcase Nord Anglia Education’s pioneering metacognition research project involving 27 schools in 17 countries.

Metacognition is being aware of and controlling one’s own learning processes. Studies have shown that metacognition can greatly enhance student learning.

“Metacognition bridges the gap between knowledge and understanding,” says Dr Kate Erricker. “By teaching students to be aware of how they think and learn, we’re not just enhancing their academic performance but also preparing them for future challenges.”

Emma Coleman, Research Lead at Nord Anglia Education, is working with the participating schools to integrate metacognitive strategies. She explains: “By embedding metacognitive practices into everyday classroom activities, we’re creating a generation of learners who are not only academically capable but also self-aware and resilient. This project showcases the incredible potential of reflective learning on a global scale.”

The workshop will give educators practical tools and insights to bring metacognitive practices into their classrooms to improve student learning and engagement. The participating Nord Anglia schools offer valuable lessons on the benefits and challenges of using metacognition in different international settings, which participants may not have had access to elsewhere.

Dr Damian Bebell says: “Our metacognition research with Nord Anglia seeks to create a more reflective and adaptable learning environment. By understanding their own thought processes, students and their teachers can take control of their educational journey and thrive in diverse settings.”

About Nord Anglia Education:

As a leading international schools organisation, we're shaping a generation of creative and resilient global citizens who graduate from our schools with everything they need for success, whatever they choose to be or do in life.

Our strong academic foundations combine world-class teaching and curricula with cutting-edge technology and facilities, creating learning experiences like no other. Inside and outside of the classroom, we inspire our students to achieve more than they ever thought possible.

No two children learn the same way, which is why our schools around the world personalise learning to what works best for every student. Inspired by our high-quality teachers, our students achieve outstanding academic results and go on to study at the world's top universities.

To learn more or apply for a place for your child, go to www.nordangliaeducation.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240712466125/en/

Contacts

Media enquiries:
Francesca Milani
Communications Manager
+44 20 7131 0000
francesca.milani@nordanglia.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release

Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr

SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un

Cranium AI and ISTARI Forge Global Alliance to Drive Enterprise AI Security and Governance21.5.2026 13:00:00 EEST | Press release

Cranium AI, the leading end-to-end AI Security and Governance platform, and ISTARI, a leading cyber resilience advisory firm, today announced a strategic partnership to provide global organizations with an end-to-end AI security & governance solution. As organizations accelerate AI adoption, they face a critical challenge: implementing actionable, operational AI governance while keeping pace with the speed of the AI landscape. This collaboration bridges that gap by merging Cranium’s cutting-edge AI security and governance platform with ISTARI’s deep advisory expertise in cyber risk and operating model design. Together, the firms provide a powerful, end-to-end solution for enterprises navigating the complexities of AI transformation. A Unified Vision for Sustainable AI Governance The partnership is built on a shared mission to move organizations beyond fragmented AI initiatives toward fully operationalized, secure, and governed programs. By combining Cranium’s platform automation with I

Cognite and ABB Collaborate to Integrate Agentic AI into Industrial Applications to Deliver Faster Workflows21.5.2026 13:00:00 EEST | Press release

Cognite, the leader in Industrial AI, today announced a collaboration with ABB to assess how advanced industrial AI and data capabilities can be integrated to solve key use cases in the energy sector. By adding an agentic layer to established industrial applications, including ABB Ability™ SafetyInsight™ and ABB Ability™ AlarmInsight™, using the Cognite Industrial AI and Data platform, the collaboration aims to enable "agent-to-agent" orchestration. Leading energy producer Aker BP has signed on as the first customer to implement this new generation of intelligent offerings as part of its strategy to further increase its current production efficiency of 96% and achieve a production growth target of 525,000 barrels of oil equivalent per day by 2028. Transforming Data into Actionable Business Value By breaking down traditional data silos and shifting to outcome-based software orchestration, the collaboration aims to deliver significant business value to ABB and Cognite customers, includin

BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts21.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that more than 60 abstracts across hematologic malignancies and solid tumors have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago) and the 2026 European Hematology Association (EHA) Congress (June 11–14, Stockholm). Continuing to raise the bar in CLL At ASCO and EHA 2026, BeOne will showcase its hematology leadership with data spanning foundational therapies and next-generation innovation across CLL, mantle cell lymphoma and other B-cell malignancies. The data emphasize impressive long-term outcomes, durability across patient populations, and a disciplined approach to advancing future regimens. Collectively, these data underscore BeOne’s strategy to lead in hematology science and patient impact by setting the standard today – while helping to shape the future of CLL. Amit Agarwal, M.D., Ph.D., Chief Medic

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye